Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk's New Weight Loss Drug Shows Ominous Psychiatric Side Effects
Novo Nordisk, the manufacturer behind Ozempic and Wegovy, has another weight loss medication in the works with some unsettling side effects.
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results
Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment showed less effectiveness in higher doses.
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Novo Shares Fall on Safety Data for New Weight-Loss Drug
Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation weight-loss drugs.
Viking, Structure, Terns benefiting from disappointing Novo Nordisk weight loss data
Structure Therapeutics (NASDAQ:GPCR), and Terns Pharmaceuticals (NASDAQ:TERN), which are all developing oral pills as weight loss treatments, are trading higher Friday following disappointing results from a rival Novo Nordisk (NVO) drug.
High-Flying Novo Nordisk Dips On Disappointing Data for Weight-Loss Pill
Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people lose weight in the mid-stage study,
1d
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
1d
J.P. Morgan Sticks to Their Buy Rating for Novo Nordisk (0QIU)
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Secret Service admits failure
Accepts CNN debate invite
Released after guilty plea
J&J unit files for bankruptcy
FBI agents board vessel
Sesame Place suit verdict
Russia threatens retaliation
$230 million crypto theft
Feds subpoena Schaeffer
TN abortion law blocked
Bill to boost security OK'd
Disney to stop using Slack
In-person voting begins
Baby powder recalled
Beirut strike death toll
ISR strike on Gaza school
Rallies in North Carolina
Hand count approved in GA
Top Hezbollah leader killed?
Drug price challenge revived
Pandas leaving for China
WI high court to decide
Stein's ballot bid rejected
SC 1st execution in 13 years
Sues pharmacy middlemen
Boeing defense chief exits
144K+ Mavericks recalled
House repeals emission rules
FDA approves flu vaccine
1st rabies outbreak in seals
Hiker injured in bear attack
Feedback